-
Non-Small Cell Lung Cancer Pipeline, Clinical Trials, Emerging Drugs Approvals and Companies | DelveInsight
22 Jan 2025 10:41 GMT
… Lung Cancer treatment.
• The leading Non-Small Cell Lung Cancer … deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) … Cell Lung Cancer Clinical Trials Assessment
Non-Small-Cell Lung cancer … lung cancer.
Learn more about Non-Small Cell Lung Cancer …
-
Roles of SPOCK1 in the Formation Mechanisms and Treatment of Non-Small-Cell Lung Cancer and Brain Metastases from Lung Cancer
15 Jan 2025 20:05 GMT
… target for osimertinib-resistant lung tumors. In recent years, … greater than that of docetaxel in patients with CNS … -translocated non-small cell lung cancers and long-term responses … non-squamous non-small cell lung cancer. Lung Cancer. 2019;129:35–40 …
-
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
13 Jan 2025 12:20 GMT
… small cell lung cancer
Nearly 2.5 million lung cancer cases were … of datopotamab deruxtecan versus docetaxel in adult patients with … breast cancer, small cell lung cancer, urothelial, gastric, pancreatic, … in non-small cell lung cancers and its correlationn …
-
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
13 Jan 2025 07:07 GMT
… antibody drug conjugate for lung cancer, providing a promising … of datopotamab deruxtecan versus docetaxel in adult patients … breast cancer, small cell lung cancer, urothelial, gastric, pancreatic, … Small Cell Lung Cancer
Nearly 2.5 million lung cancer cases …
-
AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment
26 Dec 2024 19:29 GMT
… advanced nonsquamous non-small cell lung cancer (NSCLC).
Dato-DXd is intended … safety of the asset against docetaxel in adults with advanced or … progression-free survival (PFS) over docetaxel.
Despite the promising data, the …
-
Prostate Cancer Bone Metastasis: Molecular Mechanisms of Tumor and Bone Microenvironment
01 Feb 2025 10:18 GMT
… -cadherin expression in lung cancer by stabilizing the … that had progressed after docetaxel chemotherapy (CA184-043 … inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in … intetumumab) in combination with docetaxel and prednisone for the …
-
Repurposed Drug Shows Promise for Lung Cancer
10 Dec 2024 10:42 GMT
… a major subset of lung cancer patients.
“This novel … Society. About 85% of lung cancer patients have the NSCLC … treatments for KRAS mutant lung cancer remain a major unmet … docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer …
-
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
09 Dec 2024 12:13 GMT
… small cell lung cancer
Nearly 2.5 million lung cancer cases were … of datopotamab deruxtecan versus docetaxel in adult patients with … improvements for people with lung cancer, including and beyond treatment … in non-small cell lung cancers and its correlation with …
-
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
09 Dec 2024 07:20 GMT
… of datopotamab deruxtecan versus docetaxel in adult patients with … 2024 World Conference on Lung Cancer hosted by the International … for the Study of Lung Cancer (#WCLC24) and simultaneously … Small Cell Lung Cancer
Nearly 2.5 million lung cancer cases were …
-
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis
06 Dec 2024 02:27 GMT
… mutated non-small cell lung cancer with disease progression … deruxtecan in later-line lung cancer settings.”
Patients in … of datopotamab deruxtecan versus docetaxel in adult patients with … Small Cell Lung Cancer
Nearly 2.5 million lung cancer cases were …
About
© 1995-2025